On the day dedicated to the battle against the deadly disease – took to reaching the public of Pune to understand that cancer can be prevented and even reversed with the help of adequate testing
Experts’ conclave to pave holistic approach to cancer management
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Subscribe To Our Newsletter & Stay Updated
